GLOW-70 — GHK-Cu + BPC-157 + TB-500 blend, 70 mg

A co-lyophilized research blend combining GHK-Cu, BPC-157 and TB-500, formulated to explore the combination of tissue-repair and matrix-remodelling pathways. 70 mg total per vial, lyophilized powder, ≥99% HPLC purity verified by third-party analysis. Laboratory research use only.

Research areas

• Repair / matrix synergy
• In-vitro skin models
• Multi-peptide co-formulation

Technical data

70 mg of what, exactly: read the split before comparing

This is the confusion the blend format creates almost mechanically. A vial labelled 70 mg looks seven times better stocked than a 10 mg BPC-157 vial. The two numbers do not describe the same thing: one is a total mass shared between three molecules, the other the mass of a single peptide.

The trap: "GLOW-70" is not a standard. No body guarantees the split behind the name, and two vials carrying the same label can hold different proportions. The only check that settles it is the batch COA, which must state the three masses separately. A certificate limited to "70 mg total, ≥99% purity" says nothing about the actual composition.

A second check applies to the third component: TB-500 refers, depending on the source, either to the short LKKTET fragment or to full-length thymosin β4 (43 amino acids) — two distinct molecules roughly a factor of five apart in mass. The component used in this blend is full-length thymosin β4, the form the literature actually covers.

Mechanisms studied

GHK-Cu is a tripeptide — glycyl-L-histidyl-L-lysine — complexed with a copper ion, naturally present in human plasma at concentrations that decline with age. The literature describes it as a modulator of gene expression: a large-scale analysis on fibroblast cultures reported altered expression of a large number of human genes, many tied to extracellular matrix composition, and it is also described as stimulating growth-factor secretion (bFGF, VEGF).

BPC-157 is a pentadecapeptide derived from a gastric protein sequence. A mechanistic detail often misreported: in rodent work it shows no direct angiogenic effect on isolated cell cultures. The angiogenesis observed is indirect, associated in vivo with upregulated VEGF expression during muscle and tendon healing.

TB-500 / thymosin β4 acts as a G-actin-binding protein: by holding actin in monomeric form it maintains a mobilisable pool supporting the polymerisation required for fibroblast, keratinocyte and endothelial cell migration.

The blend's rationale is the complementarity of these axes: matrix for GHK-Cu, indirect vascularisation for BPC-157, cell migration for thymosin β4.

What the literature shows

The evidence type differs by molecule. GHK-Cu: mostly in vitro (fibroblasts, keratinocytes) and animal (rodent and rabbit wound models), describing accelerated wound closure and matrix recomposition; human skin data come mainly from topical cosmetics. BPC-157: almost entirely preclinical, chiefly Wistar rats, on induced tendon, muscle and gastrointestinal lesions, with very limited controlled human studies. TB-500 / thymosin β4: accelerated cutaneous and corneal healing, cardiac repair and reduced scarring in animal models, with human clinical data scarce.

What the literature does not show — the key point for a blend. No publication evaluates the interactions between these three peptides administered together: everything above was obtained molecule by molecule, in isolation. A blend's "synergy" is a working hypothesis, not a documented result. The usual limits apply on top: heterogeneous protocols, unestablished extrapolation to humans, and batch-to-batch standardisation variability.

Reconstitution: a worked example

With 2 mL of bacteriostatic water in a 70 mg vial: 70 mg ÷ 2 mL = 35 mg/mL, i.e. 35,000 mcg/mL of total peptides. On a U-100 syringe, 10 IU = 0.1 mL = 3,500 mcg total, giving 20 draws per vial. Applying the 50 / 10 / 10 split, a 10 IU draw holds roughly 2,500 mcg GHK-Cu, 500 mcg BPC-157 and 500 mcg thymosin β4 — a ratio fixed at co-lyophilization, identical whatever volume is drawn.

The most common trap: the volume of water never changes how much peptide is in the vial. Using 4 mL instead of 2 mL gives 17.5 mg/mL instead of 35 mg/mL — the same total mass in twice the volume; only the graduation changes. Our reconstitution calculator computes any other combination live.

Add the solvent slowly down the vial wall, then swirl gently. No vigorous shaking, no vortex — shear denatures peptides. The copper in GHK-Cu gives the solution a characteristic bluish tint: expected, not an anomaly.

Storage

Lyophilized powder: -20 °C or below, protected from light and moisture; stable for years when unopened. After reconstitution: 2–8 °C, protected from light, with a reference shelf life of 28 days. For longer storage, frozen aliquots are preferable to repeated freeze-thaw cycles.

Common laboratory mistakes

• Comparing the blend's 70 mg with a 10 mg single-peptide vial. The 70 mg cover three molecules; the per-component fraction is what should be compared.
• Assuming a split without reading the COA. "GLOW-70" is not a standard; only the batch certificate states the masses actually present.
• Confusing the LKKTET fragment with full-length thymosin β4. Two distinct molecules, roughly a factor of five apart in mass.
• Trying to dose one component independently. The ratio is fixed at co-lyophilization; only the total volume drawn can change.
• Mistaking the blue tint for contamination. It comes from the copper ion in GHK-Cu. Persistent cloudiness or undissolved material, however, warrants discarding the vial.